UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad…
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage…
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti…
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is…
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024…
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the…
The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ETNEW YORK, April…
Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for…
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also…